Recently, Goel et al. [47] reviewed that anti-VEGF therapy in preclinical studies caused changes in the tumor vasculature towards a more “mature” or “normal” phenotype characterized by attenuation of hyperpermeability, increased vascular pericyte coverage, a more normal basement membrane, and a reduction in tumor hypoxia and interstitial fluid pressure. This evidence concerns the gene VEGFA and neoplasm.